# Compass Therapeutics Inc. (CMPX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.38, market value $429 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Compass Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.6×**. The shares trade at 2.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -13.2%** (5-yr avg -13.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -33.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -34.6%**. Return on all capital, debt included, is -34.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -30.3%**. Each dollar of assets produces -30.3% of profit.

## Growth
- **Revenue growth (1 yr): -100.0%**. Revenue fell 100.0% over the last year.
- **EPS growth (1 yr): -16.7%**. Earnings per share fell 16.7%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 15.02** (quick 15.02). Current assets cover the next year's liabilities 15.02 times.
- **Altman Z-score: 12.51**. A Z-score of 12.51 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Compass Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Compass Therapeutics Inc.; the consensus is strong_buy, with an average price target of $8.92 (+275% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -29.4%** (YTD -55.7%, 3-mo 16.7%). The shares are down 29.4% over twelve months including dividends.
- **From 52-week high: -65.4%** (47.8% above the low). Trading 65% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.18** (volatility 90%). Beta of 1.18 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CMPX · Page: https://foliofundamentals.com/stocks/cmpx

Not investment advice.